Photoactivation of MDM2 Inhibitors: Controlling Protein-Protein Interaction with Light
Mickel J Hansen1, Femke M Feringa2, Piermichele Kobauri1
1Centre for Systems Chemistry , Stratingh Institute for Chemistry, University of Groningen , Nijenborgh 4 , 9747 AG , Groningen , The Netherlands.
Abstract:
Selectivity remains a major challenge in anticancer therapy, which potentially can be overcome by local activation of a cytotoxic drug. Such triggered activation can be obtained through modification of a drug with a photoremovable protecting group (PPG), and subsequent irradiation in the chosen place and time. Herein, the design, synthesis and biological evaluation is described of a photoactivatable MDM2 inhibitor, PPG-idasanutlin, which exerts no functional effect on cellular outgrowth, but allows for the selective, noninvasive activation of antitumor properties upon irradiation visible light, demonstrating activation with micrometer, single cell precision. The generality of this method has been demonstrated by growth inhibition of multiple cancer cell lines showing p53 stabilization and subsequent growth inhibition effects upon irradiation. Light activation to regulate protein-protein interactions between MDM2 and p53 offers exciting opportunities to control a multitude of biological processes and has the potential to circumvent common selectivity issues in antitumor drug development.
Insights
Researchers developed a photoactivatable drug that precisely targets cancer cells using light. This approach enhances anticancer therapy selectivity by activating the drug only where needed, minimizing side effects.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Anticancer therapy often struggles with selectivity, leading to off-target effects.
- Local drug activation can improve therapeutic precision and reduce toxicity.
Purpose of the Study:
- To design and synthesize a photoactivatable MDM2 inhibitor for targeted cancer treatment.
- To evaluate the selective activation and antitumor efficacy of the photoactivatable drug.
Main Methods:
- Modification of idasanutlin with a photoremovable protecting group (PPG).
- In vitro testing of PPG-idasanutlin's biological activity upon visible light irradiation.
- Assessment of cancer cell line growth inhibition and p53 stabilization.
Main Results:
- PPG-idasanutlin showed no effect on cellular outgrowth without light.
- Selective, noninvasive activation of antitumor properties was achieved with visible light.
- Demonstrated micrometer and single-cell precision activation.
- Inhibited growth in multiple cancer cell lines via p53 stabilization.
Conclusions:
- Photoactivatable drugs offer a promising strategy to overcome selectivity challenges in cancer therapy.
- Light-triggered activation of MDM2 inhibitors provides precise control over antitumor responses.
- This method has broad potential for developing targeted cancer treatments.
Related Concept Videos
02:04Protein-protein Interfaces
02:15Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
01:55What are Proteins?
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
02:26Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...